NEW YORK (GenomeWeb News) — Interleukin Genetics said after the close of market Thursday that its fourth quarter revenues nearly doubled year over year on increased royalty income and genetic testing revenue through the Amway Global sales channel.

Revenues for the three months ended Dec. 31, 2013, were $671,000 compared to $339,000 in the year-ago period. Genetic testing service revenue totaled $424,000 in the quarter, up from $317,000 in Q4 2012, while other revenues jumped to $247,000 from $22,000 in the prior-year period.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The NIH has issued a preliminary guidance for newborn dried blood spot research.

Wired writes that CRISPR could change the world — in many imaginative ways — and whether it will be for the better is still in the air.

In PLOS this week: locus linked to non-syndromic hearing loss, phylogenetic relationships of Klebsiella pneumoniae isolates, and more.

In a column at Nature, researcher Fyodor Kondrashov worries about the influence of politics on Russian science.